362 related articles for article (PubMed ID: 34876572)
1. Plasmin activity promotes amyloid deposition in a transgenic model of human transthyretin amyloidosis.
Slamova I; Adib R; Ellmerich S; Golos MR; Gilbertson JA; Botcher N; Canetti D; Taylor GW; Rendell N; Tennent GA; Verona G; Porcari R; Mangione PP; Gillmore JD; Pepys MB; Bellotti V; Hawkins PN; Al-Shawi R; Simons JP
Nat Commun; 2021 Dec; 12(1):7112. PubMed ID: 34876572
[TBL] [Abstract][Full Text] [Related]
2. In Vitro and In Vivo Effects of SerpinA1 on the Modulation of Transthyretin Proteolysis.
Bezerra F; Niemietz C; Schmidt HHJ; Zibert A; Guo S; Monia BP; Gonçalves P; Saraiva MJ; Almeida MR
Int J Mol Sci; 2021 Aug; 22(17):. PubMed ID: 34502397
[TBL] [Abstract][Full Text] [Related]
3. Plasminogen activation triggers transthyretin amyloidogenesis
Mangione PP; Verona G; Corazza A; Marcoux J; Canetti D; Giorgetti S; Raimondi S; Stoppini M; Esposito M; Relini A; Canale C; Valli M; Marchese L; Faravelli G; Obici L; Hawkins PN; Taylor GW; Gillmore JD; Pepys MB; Bellotti V
J Biol Chem; 2018 Sep; 293(37):14192-14199. PubMed ID: 30018138
[TBL] [Abstract][Full Text] [Related]
4. Amyloid seeding of transthyretin by ex vivo cardiac fibrils and its inhibition.
Saelices L; Chung K; Lee JH; Cohn W; Whitelegge JP; Benson MD; Eisenberg DS
Proc Natl Acad Sci U S A; 2018 Jul; 115(29):E6741-E6750. PubMed ID: 29954863
[TBL] [Abstract][Full Text] [Related]
5. A cell-based high-throughput screening method to directly examine transthyretin amyloid fibril formation at neutral pH.
Ueda M; Okada M; Mizuguchi M; Kluve-Beckerman B; Kanenawa K; Isoguchi A; Misumi Y; Tasaki M; Ueda A; Kanai A; Sasaki R; Masuda T; Inoue Y; Nomura T; Shinriki S; Shuto T; Kai H; Yamashita T; Matsui H; Benson MD; Ando Y
J Biol Chem; 2019 Jul; 294(29):11259-11275. PubMed ID: 31167790
[TBL] [Abstract][Full Text] [Related]
6. Cryo-EM structure of a transthyretin-derived amyloid fibril from a patient with hereditary ATTR amyloidosis.
Schmidt M; Wiese S; Adak V; Engler J; Agarwal S; Fritz G; Westermark P; Zacharias M; Fändrich M
Nat Commun; 2019 Nov; 10(1):5008. PubMed ID: 31676763
[TBL] [Abstract][Full Text] [Related]
7. Tafamidis: a selective transthyretin stabilizer to treat wild-type ATTR amyloidosis and hereditary ATTR amyloidosis with cardiomyopathy.
Paton DM
Drugs Today (Barc); 2019 Dec; 55(12):727-734. PubMed ID: 31942875
[TBL] [Abstract][Full Text] [Related]
8. Deposition of transthyretin amyloid is not accelerated by the same amyloid in vivo.
Wei L; Kawano H; Fu X; Cui D; Ito S; Yamamura K; Ishihara T; Tokuda T; Higuchi K; Maeda S
Amyloid; 2004 Jun; 11(2):113-20. PubMed ID: 15478467
[TBL] [Abstract][Full Text] [Related]
9. Effect of albumin on transthyretin and amyloidogenic transthyretin Val30Met disposition and tissue deposition in familial amyloidotic polyneuropathy.
Taguchi K; Jono H; Kugimiya-Taguchi T; Nagao S; Su Y; Yamasaki K; Mizuguchi M; Maruyama T; Ando Y; Otagiri M
Life Sci; 2013 Dec; 93(25-26):1017-22. PubMed ID: 24211615
[TBL] [Abstract][Full Text] [Related]
10. Transthyretin (ATTR) amyloidosis: clinical spectrum, molecular pathogenesis and disease-modifying treatments.
Sekijima Y
J Neurol Neurosurg Psychiatry; 2015 Sep; 86(9):1036-43. PubMed ID: 25604431
[TBL] [Abstract][Full Text] [Related]
11. Structural basis for transthyretin amyloid formation in vitreous body of the eye.
Iakovleva I; Hall M; Oelker M; Sandblad L; Anan I; Sauer-Eriksson AE
Nat Commun; 2021 Dec; 12(1):7141. PubMed ID: 34880242
[TBL] [Abstract][Full Text] [Related]
12. Cardiac Amyloidosis Due to Transthyretin Protein: A Review.
Ruberg FL; Maurer MS
JAMA; 2024 Mar; 331(9):778-791. PubMed ID: 38441582
[TBL] [Abstract][Full Text] [Related]
13. Amyloid Cardiomyopathy in Hereditary Transthyretin V30M Amyloidosis - Impact of Sex and Amyloid Fibril Composition.
Arvidsson S; Pilebro B; Westermark P; Lindqvist P; Suhr OB
PLoS One; 2015; 10(11):e0143456. PubMed ID: 26600306
[TBL] [Abstract][Full Text] [Related]
14. CNS involvement in V30M transthyretin amyloidosis: clinical, neuropathological and biochemical findings.
Maia LF; Magalhães R; Freitas J; Taipa R; Pires MM; Osório H; Dias D; Pessegueiro H; Correia M; Coelho T
J Neurol Neurosurg Psychiatry; 2015 Feb; 86(2):159-67. PubMed ID: 25091367
[TBL] [Abstract][Full Text] [Related]
15. Preclinical evaluation of RNAi as a treatment for transthyretin-mediated amyloidosis.
Butler JS; Chan A; Costelha S; Fishman S; Willoughby JL; Borland TD; Milstein S; Foster DJ; Gonçalves P; Chen Q; Qin J; Bettencourt BR; Sah DW; Alvarez R; Rajeev KG; Manoharan M; Fitzgerald K; Meyers RE; Nochur SV; Saraiva MJ; Zimmermann TS
Amyloid; 2016 Jun; 23(2):109-18. PubMed ID: 27033334
[TBL] [Abstract][Full Text] [Related]
16. Sporadic Cardiac Amyloidosis by Amyloidogenic Transthyretin V122I Variant.
Nehashi T; Oikawa M; Amami K; Kanno Y; Yokokawa T; Misaka T; Yamada S; Kunii H; Nakazato K; Ishida T; Takeishi Y
Int Heart J; 2019 Nov; 60(6):1441-1443. PubMed ID: 31666456
[TBL] [Abstract][Full Text] [Related]
17. One mutation, two distinct disease variants: unravelling the impact of transthyretin amyloid fibril composition.
Suhr OB; Lundgren E; Westermark P
J Intern Med; 2017 Apr; 281(4):337-347. PubMed ID: 28093848
[TBL] [Abstract][Full Text] [Related]
18. Transthyretin amyloid deposits in lumbar spinal stenosis and assessment of signs of systemic amyloidosis.
Eldhagen P; Berg S; Lund LH; Sörensson P; Suhr OB; Westermark P
J Intern Med; 2021 Jun; 289(6):895-905. PubMed ID: 33274477
[TBL] [Abstract][Full Text] [Related]
19. Novel conformation-specific monoclonal antibodies against amyloidogenic forms of transthyretin.
Higaki JN; Chakrabartty A; Galant NJ; Hadley KC; Hammerson B; Nijjar T; Torres R; Tapia JR; Salmans J; Barbour R; Tam SJ; Flanagan K; Zago W; Kinney GG
Amyloid; 2016 Jun; 23(2):86-97. PubMed ID: 26981744
[TBL] [Abstract][Full Text] [Related]
20. Modeling transthyretin (TTR) amyloid diseases, from monomer to amyloid fibrils.
Criddle RS; Hansen LD; Woodfield BF; Tolley HD
PLoS One; 2024; 19(6):e0304891. PubMed ID: 38843135
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
